Search for other papers by Ina Gajic in
Current site
Google Scholar
PubMed
Search for other papers by Lazar Ranin in
Current site
Google Scholar
PubMed
Search for other papers by Dusan Kekic in
Current site
Google Scholar
PubMed
Search for other papers by Natasa Opavski in
Current site
Google Scholar
PubMed
Search for other papers by Aleksandra Smitran in
Current site
Google Scholar
PubMed
Search for other papers by Vera Mijac in
Current site
Google Scholar
PubMed
Search for other papers by Snezana Jovanovic in
Current site
Google Scholar
PubMed
Search for other papers by Mirjana Hadnadjev in
Current site
Google Scholar
PubMed
Department of Microbiology, Clinical Centre of Banja Luka,
Search for other papers by Maja Travar in
Current site
Google Scholar
PubMed
Search for other papers by Gordana Mijovic in
Current site
Google Scholar
PubMed
Abstract
Tigecycline can be effective to treat infections of carbapenem-resistant Acinetobacter baumannii (CRAB) however, no interpretive criteria have been approved so far. The objectives of this study were to evaluate the proportion of CRAB isolates and to compare gradient test with a broth microdilution (BMD) method for tigecycline susceptibility testing of A. baumannii.
This study included 349 multidrug-resistant (MDR) Acinetobacter spp. collected from Serbia, Montenegro, Bosnia and Herzegovina in 2016 and 2017. Antibiotic susceptibility testing was performed by disk diffusion, VITEK2, gradient, ComASP Colistin. Tigecycline susceptibilities were interpreted according to breakpoints of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Food and Drug Administration (FDA).
Majority of the tested isolates were CRAB (92.8%). Tigecycline MIC50/MIC90 values were 4/8 μg/mL by BMD and 0.5/4 μg/mL by gradient test. Essential agreement for BMD and gradient test amounted to 65.1%. With EUCAST breakpoints, categorical agreement (CA) was achieved in 38% isolates. Major discordance (MD-false susceptibility/resistance) and minor discordance (mD-false categorization involving intermediate results) were observed in 10% and 57% A. baumannii, respectively. With FDA breakpoints, CA, MD and mD were observed in 44%, 16% and 47% isolates, respectively. Colistin resistance was 2.1%.
The study highlights a high proportion of CRAB and several discordances between BMD and gradient test which may lead to inappropriate therapy.
-
[1]
Doi Y, Murray GL, Peleg AY. Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options. Semin Respir Crit Care Med 2015; 36: 85–98.
-
[2]
Organization WHO. WHO publishes list of bacteria for which new antibiotics are urgently needed. Geneva: WHO; 2017.
-
[3]
Clark NM, Zhanel GG, Lynch JP. Emergence of antimicrobial resistance among Acinetobacter species: a global threat. Curr Opin Crit Care 2016; 22: 491–499.
-
[4]
De Angelis GD, D'Inzeo T, Fiori B, Spanu T, Sganga G. Burden of antibiotic resistant gram negative bacterial infections: evidence and limits. J Med Microbiol Diagn 2014; 3: 132.
-
[5]
Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspect Medicin Chem 2014; 6: 25–64.
-
[6]
Xie R, Zhang XD, Zhao Q, Peng B, Zheng J. Analysis of global prevalence of antibiotic resistance in Acinetobacter baumannii infections disclosed a faster increase in OECD countries. Emerg Microbes Infect 2018; 7: 31.
-
[7]
Djordjevic ZM, Folic MM, Jankovic SM. Previous antibiotic exposure and antimicrobial resistance patterns of Acinetobacter spp. and Pseudomonas aeruginosa isolated from patients with nosocomial infections. Balkan Med J 2017; 34: 527–533.
-
[8]
Viehman JA, Nguyen MH, Doi Y. Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections. Drugs 2014; 74: 1315–1333.
-
[9]
Doi Y, Murray GL, Peleg AY. Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options. Semin Respir Crit Care Med 2015; 36: 85–98.
-
[10]
Stein GE, Babinchak T. Tigecycline: an update. Diagn Microbiol Infect Dis 2013; 75: 331–336.
-
[11]
Pfizer Inc. Tygacil. Tigecycline FDA prescribing information. Collegeville, PA: Pfizer Inc.; 2016.
-
[12]
European Medicines Agency. Tygacil: EPAR summary for the public. Report number EMA/340933/2015. London, United Kingdom: European Medicines Agency; 2015.
-
[13]
Kulah C, Celebi G, Aktas E, Mengeloglu Z, Comert F, Ankarali H. Unexpected tigecycline resistance among Acinetobacter baumannii isolates: high minor error rate by Etest. J Chemother 2009; 21: 390–395.
-
[14]
Liu JW, Ko WC, Huang CH, Liao CH, Lu CT, Chuang YC, et al. Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates: results from the tigecycline in vitro surveillance in Taiwan (TIST) study, 2008 to 2010. Antimicrob Agents Chemother 2012; 56: 1414–1417.
-
[15]
Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, twenty-sixth informational supplement. Wayne, PA: CLSI Document M100S Clinical Laboratory Standards Institute; 2016.
-
[16]
Turton JF, Woodford N, Glover J, Yarde S, Kaufmann ME, Pitt TL. Identification of Acinetobacter baumannii by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. J Clin Microbiol 2006; 44: 2974–2976.
-
[17]
Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 10th ed. Wayne, PA: M07-A11 Clinical and Laboratory Standards Institute; 2018.
-
[18]
European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0, valid from 2016-01-01; Pfizer Inc. Collegeville, PA: Tygacil. Tigecycline FDA Prescribing Information. Pfizer Inc.; 2016.
-
[19]
Flamm RK, Castanheira M, Streit JM, Jones RN. Minocycline activity tested against Acinetobacter baumannii complex, Stenotrophomonas maltophilia, and Burkholderia cepacia species complex isolates from a global surveillance program (2013). Diagn Microbiol Infect Dis 2016; 85: 352–355.
-
[20]
Clinical and Laboratory Standards Institute. Development of in vitro susceptibility testing criteria and quality control parameters. 4th ed. M23-A4. Wayne, PA: Clinical and Laboratory Standards Institute; 2016.
-
[21]
Abbott I, Cerqueira GM, Bhuiyan S, Peleg AY. Carbapenem resistance in Acinetobacter baumannii: laboratory challenges, mechanistic insights and therapeutic strategies. Expert Rev Anti Infect Ther 2013; 11: 395–409.
-
[22]
Ku K, Pogue JM, Moshos J, Bheemreddy S, Wang Y, Bhargava A, et al. Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections. Am J Infect Control 2012; 40: 983–987.
-
[23]
Pourabbas B, Firouzi R, Pouladfar G. Characterization of carbapenem-resistant Acinetobacter calcoaceticus-baumannii complex isolates from nosocomial bloodstream infections in southern Iran. J Med Microbiol 2016; 65: 235–239.
-
[24]
Tucker H, Wible M, Gandhi A, Quintana A. Efficacy of intravenous tigecycline in patients with Acinetobacter complex infections: results from 14 phase III and phase IV clinical trials. Infect Drug Resist 2017; 10: 401–417.
-
[25]
Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007; 59: 772–774.
-
[26]
Tas T, Kocoglu E, Mengeloglu Z, Bucak O, Karabörk S. Investigation of in-vitro susceptibility of multidrug-resistant Acinetobacter baumannii strains isolated from clinical specimens to tigecycline. Bosn J Basic Med Sci 2013; 13: 266–270.
-
[27]
Zarkotou O, Pournaras S, Altouvas G, Pitiriga V, Tziraki M, Mamali V, et al. Comparative evaluation of tigecycline susceptibility testing methods for expanded-spectrum cephalosporin- and carbapenem-resistant gram-negative pathogens. J Clin Microbiol 2012; 50: 3747–3750.
-
[28]
Veenemans J, Mouton JW, Kluytmans JA, Donnely R, Verhulst C, van Keulen PH. Effect of manganese in test media on in vitro susceptibility of Enterobacteriaceae and Acinetobacter baumannii to tigecycline. J Clin Microbiol 2012; 50: 3077–3079.
Editorial Office:
Akadémiai Kiadó Zrt.
Budafoki út 187-187, A/3, H-1117 Budapest, Hungary
Editorial Correspondence:
Acta Microbiologica et Immunologica Hungarica
Institute of Medical Microbiology
Semmelweis University
P.O. Box 370
H-1445 Budapest, Hungary
Phone: + 36 1 459 1500 ext. 56101
Fax: (36 1) 210 2959
E-mail: amih@med.semmelweis-univ.hu
Indexing and Abstracting Services:
- Biological Abstracts
- BIOSIS Previews
- CAB Abstracts
- CABELLS Journalytics
- Chemical Abstracts
- Global Health
- Index Medicus
- Index Veterinarius
- Medline
- Referativnyi Zhurnal
- SCOPUS
- Science Citation Index Expanded
| 2023 | |
|---|---|
| Web of Science | |
| Journal Impact Factor | 1.3 |
| Rank by Impact Factor | Q4 (Immunology) |
| Journal Citation Indicator | 0.31 |
| Scopus | |
| CiteScore | 2.3 |
| CiteScore rank | Q3 (Infectious Diseases) |
| SNIP | 0.389 |
| Scimago | |
| SJR index | 0.308 |
| SJR Q rank | Q3 |
| Acta Microbiologica et Immunologica Hungarica | |
|---|---|
| Publication Model | Hybrid |
| Submission Fee | none |
| Article Processing Charge | 1100 EUR/article (only for OA publications) |
| Regional discounts on country of the funding agency | World Bank Lower-middle-income economies: 50% World Bank Low-income economies: 100% |
| Further Discounts | Editorial Board / Advisory Board members: 50% Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100% |
| Subscription fee 2025 | Online subsscription: 772 EUR / 848 USD Print + online subscription: 860 EUR / 944 USD |
| Subscription Information | Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content. |
| Purchase per Title | Individual articles are sold on the displayed price. |
| Acta Microbiologica et Immunologica Hungarica | |
|---|---|
| Language | English |
| Size | A4 |
| Year of Foundation |
1954 |
| Volumes per Year |
1 |
| Issues per Year |
4 |
| Founder | Magyar Tudományos Akadémia |
| Founder's Address |
H-1051 Budapest, Hungary, Széchenyi István tér 9. |
| Publisher | Akadémiai Kiadó |
| Publisher's Address |
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245. |
| Responsible Publisher |
Chief Executive Officer, Akadémiai Kiadó |
| ISSN | 1217-8950 (Print) |
| ISSN | 1588-2640 (Online) |
Monthly Content Usage
| Abstract Views | Full Text Views | PDF Downloads | |
|---|---|---|---|
| Jun 2024 | 48 | 0 | 1 |
| Jul 2024 | 45 | 0 | 0 |
| Aug 2024 | 34 | 0 | 0 |
| Sep 2024 | 46 | 0 | 0 |
| Oct 2024 | 181 | 0 | 0 |
| Nov 2024 | 112 | 0 | 0 |
| Dec 2024 | 10 | 0 | 0 |
Copyright Akadémiai Kiadó AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.